Neuronetics, Inc.

Neuronetics, Inc. develops and commercializes NeuroStar Advanced Therapy System, a non-invasive medical device used in psychiatric care, along with recurring treatment-session access codes and related services. The company is based in the United States and sells primarily to psychiatrists and psychiatric practices, with a small international distribution footprint.

−18,8 %

48,5 %

−26,1 %

+99,2 %

2.02

1.87

— Neuronetics, Inc.
%
NeuroStar system sales and rentals9% Capital equipment sales, rentals, upgrades, and related hardware for the NeuroStar platform.
Treatment sessions30% Recurring access codes and treatment-session revenue used with the NeuroStar system.
Clinic revenue60% Revenue from treatments performed in company-operated or affiliated clinic settings.
Other revenue1% Service, repair, research collaboration, and extended warranty revenue.

Neuronetics sells to psychiatrists, group psychiatric practices, and treatment centers that use NeuroStar to treat...

  • Psychiatrists and psychiatric practicesprimary

    Buy NeuroStar systems and treatment-session access to treat MDD patients in-office and generate recurring patient revenue.

  • Clinic operatorsprimary

    Operate treatment sites and earn clinic revenue from performed sessions and patient fees.

  • Third-party payorsprimary

    Medicare, managed care, and commercial insurers reimburse treatments and influence utilization.

  • International distributorssecondary

    Purchase and distribute products in select non-U.S. markets.

The business is overwhelmingly U.S.-centric, with the United States accounting for 98% of revenue in the nine months...

  • •United States is the core market and main revenue source
  • •International sales are small and distributor-based
  • •Clinic revenue is tied to treatment activity in 15 U.S. states
  • •Manufacturing components are outsourced, with final handling in Pennsylvania
  • •U.S. reimbursement dynamics are central to demand

Neuronetics is focused on expanding adoption of NeuroStar through direct sales coverage, customer support, and clinical...

01
Expand installed base and utilizationshort-term

More systems in the field and higher session volume increase recurring revenue opportunities.

02
Develop additional indicationsmedium-term

Broader clinical use can expand the addressable market and support adoption.

03
Scale clinic revenuemedium-term

Clinic operations add a direct patient-fee stream and deepen market penetration.

Neuronetics depends on reimbursement, physician adoption, and patient willingness to pursue treatment, so demand can be...

high

Reimbursement and payor policy risk

Clinic and treatment-session demand depend on Medicare, managed care, and commercial coverage.

Scope
U.S. psychiatric treatment reimbursement
Materiality
high
high

Manufacturing and supply chain risk

Components are produced by third-party contract manufacturers and assembled through outsourced partners.

Scope
Component availability, cost, and quality
Materiality
high
high

Product concentration risk

The business is centered on NeuroStar and related treatment-session revenue.

Scope
Single-platform dependence
Materiality
high
high

Liquidity and covenant risk

Borrowings under the Perceptive Facility include revenue and liquidity covenants.

Scope
Debt compliance and financing flexibility
Materiality
high
medium

Macroeconomic demand sensitivity

Patients may delay or forego medical services during weaker economic conditions.

Scope
Consumer and provider spending on psychiatric care
Materiality
medium
Clinic revenue estimation
Can materially affect reported revenue and receivables
Variable consideration
Creates estimation uncertainty in clinic revenue
Multiple revenue streams
Affects revenue mix and comparability across periods
Warranty and service contracts
Influences deferred revenue and service-cost estimates

NeuroPace Inc

NPCE · Surgical & Medical Instruments & Apparatus

Enveric Biosciences, Inc.

ENVB · Pharmaceutical Preparations

Neuraxis, INC

NRXS · Electromedical & Electrotherapeutic Apparatus

ClearPoint Neuro, Inc.

CLPT · Surgical & Medical Instruments & Apparatus

NRX Pharmaceuticals, Inc.

NRXP · Pharmaceutical Preparations

Neurogene Inc.

NGNE · Pharmaceutical Preparations

: 29/04/2026